Conversations from ESMO Targeted Anticancer Therapies Congress 2024
Drug Discovery World
MARCH 26, 2024
For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. In vivo, METTL1 inhibitors induce tumour growth inhibition in both immune-deficient and immune-competent mouse strains. MT: What data did you present at the conference?
Let's personalize your content